Literature DB >> 26666422

Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma.

Tae-Yong Ha1, Shin Hwang2, Young-Joo Lee1, Ki-Hun Kim1, Gi-Young Ko3, Dong Ii Gwon3, Chul-Soo Ahn1, Deok-Bog Moon1, Gi-Won Song1, Dong-Hwan Jung1, Han Chu Lee4, Young-Suk Lim4, Kang Mo Kim4, Ju Hyun Shim4, Jeong-Heon Choi1, Sung-Gyu Lee1.   

Abstract

BACKGROUND: This study aimed to assess the prognostic impact of preoperative transcatheter arterial chemoembolization (TACE) on long-term survival outcomes in patients undergoing resection of small solitary hepatocellular carcinoma (HCC).
METHODS: Enrolled patients had undergone macroscopic curative resection of solitary 2-5 cm HCC with (n = 105) or without (n = 830; control group) preoperative TACE.
RESULTS: TACE group was divided into subgroups A (n = 68, 1-2 TACEs within 12 months), B (n = 23, ≥ 3 TACEs within 12 months), and C (n = 14, TACE prior to 12 months). The number of TACE sessions was 1.8 ± 1.6. In TACE A-C subgroups, pathological response of tumor necrosis >50 % at median post-TACE period after final TACE was observed in 41 (60.3 %) at 1.9 months, 10 (43.5 %) at 2.1 months, and 2 (14.3 %) at 18.9 months, respectively. The 5-year tumor recurrence and patient survival rates were 62.8 and 70.4 % in TACE group and 51.4 and 83.4 % in control group, respectively (p ≤ 0.003). Median periods of postoperative tumor recurrence in TACE A-C subgroups and control group were 35, 13, 14, and 55 months, respectively (p < 0.001); and postoperative survival periods at 75 % survival rate were 51, 38, 51, and 98 months, respectively (p = 0.003). TACE-induced extensive tumor necrosis did not improve postoperative prognosis in TACE A subgroup (p ≥ 0.053). Postoperative prognosis after preoperative sequential TACE and portal vein embolization was comparable to that of the control group (p ≥ 0.052).
CONCLUSIONS: Preoperative TACE for small solitary HCCs may adversely affect post-resection prognosis, irrespective of pathological responses. Preoperative TACE should be avoided for patients with resectable small HCCs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26666422     DOI: 10.1007/s00268-015-3373-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  34 in total

1.  A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.

Authors:  Wei-Ping Zhou; Eric C H Lai; Ai-Jun Li; Si-Yuan Fu; Jian-Ping Zhou; Ze-Ya Pan; Wan Yee Lau; Meng-Chao Wu
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

Review 2.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

3.  Quantified Risk Assessment for Major Hepatectomy via the Indocyanine Green Clearance Rate and Liver Volumetry Combined with Standard Liver Volume.

Authors:  Shin Hwang; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Chul-Soo Ahn; Deok-Bog Moon; Ki-Hun Kim; Young-Joo Lee; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-05-07       Impact factor: 3.452

Review 4.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

7.  Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis.

Authors:  E Adachi; T Matsumata; T Nishizaki; H Hashimoto; M Tsuneyoshi; K Sugimachi
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

8.  The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes.

Authors:  King-Teh Lee; Yi-Wei Lu; Shen-Nien Wang; Hong-Yaw Chen; Shih-Chang Chuang; Wen-Tsan Chang; Hon-Yi Shi; Chen-Guo Ker; Herng-Chia Chiu
Journal:  J Surg Oncol       Date:  2009-05-01       Impact factor: 3.454

9.  Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors.

Authors:  Junichi Shindoh; Andreas Andreou; Thomas A Aloia; Giuseppe Zimmitti; Gregory Y Lauwers; Alexis Laurent; David M Nagorney; Jacques Belghiti; Daniel Cherqui; Ronnie Tung-Ping Poon; Norihiro Kokudo; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2012-11-21       Impact factor: 5.344

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  9 in total

1.  The Negative Effect of Preoperative Transcatheter Arterial Chemoembolization on Long-Term Outcomes for Resectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Authors:  Masataka Amisaki; Soichiro Honjo; Masaki Morimoto; Takehiko Hanaki; Yosuke Arai; Naruo Tokuyasu; Teruhisa Sakamoto; Yasufumi Ohuchi; Hiroaki Saito
Journal:  Yonago Acta Med       Date:  2016-12-26       Impact factor: 1.641

2.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

3.  Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.

Authors:  Chao Li; Ming-Da Wang; Lun Lu; Han Wu; Jiong-Jie Yu; Wan-Guang Zhang; Timothy M Pawlik; Yao-Ming Zhang; Ya-Hao Zhou; Wei-Min Gu; Hong Wang; Ting-Hao Chen; Jun Han; Hao Xing; Zhen-Li Li; Wan Yee Lau; Meng-Chao Wu; Feng Shen; Tian Yang
Journal:  Hepatol Int       Date:  2019-09-05       Impact factor: 6.047

4.  Guiding Value of Circulating Tumor Cells for Preoperative Transcatheter Arterial Embolization in Solitary Large Hepatocellular Carcinoma: A Single-Center Retrospective Clinical Study.

Authors:  Qiao Zhang; Feng Xia; Ali Mo; Weiming He; Jiazhen Chen; Weiqiao Zhang; Weiqiang Chen
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

5.  Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials.

Authors:  Tengfei Si; Yongjun Chen; Di Ma; Xiaoyong Gong; Kui Yang; Ruoyu Guan; Chenghong Peng
Journal:  Scand J Gastroenterol       Date:  2016-08-10       Impact factor: 2.423

6.  Long-term complete response after transcatheter arterial chemoembolization and stereotactic body radiation therapy in a patient with hepatocellular carcinoma at the caudate lobe.

Authors:  Yong-Kyu Chung; Shin Hwang; Gi-Young Ko; Sang Min Yoon
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2018-08-31

7.  Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.

Authors:  Tengfei Si; Zhenlin Huang; Shirin Elizabeth Khorsandi; Yun Ma; Nigel Heaton
Journal:  Front Bioeng Biotechnol       Date:  2022-09-27

8.  Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma.

Authors:  Min-Jae Kim; Woo-Hyoung Kang; Shin Hwang; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Gil-Chun Park
Journal:  J Clin Med       Date:  2022-10-06       Impact factor: 4.964

9.  Validation of prognostic impact of ADV score for resection of hepatocellular carcinoma: analysis using Korea Liver Cancer Registry Database.

Authors:  Gil-Chun Park; Shin Hwang; Yo-Han Park; Jin-Uk Choi
Journal:  Ann Surg Treat Res       Date:  2020-04-28       Impact factor: 1.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.